STAT+: Pharmalittle: We’re reading about fake Ozempic, the FTC policing pharma, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are hovering over the Pharmalot campus again, but our spirits remain sunny, nonetheless. Why? We recall a bit of insight from the Morning Mayor, who taught us that “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Our choice today is the oh-so-sweet chocolate raspberry. Remember, a prescription is not required. So no need to mess with rebates. Meanwhile, here are a few items of interest. Hope you have a meaningful and productive day and, of course, do stay in touch. …
Three people sought medical treatment for dangerously low blood sugar in the U.S. last year after taking suspected fake versions of Novo Nordisk’s diabetes drug Ozempic, Reuters reports, citing data from America’s Poison Centers. One person also experienced hypoglycemia in 2023 after injecting a compounded version of Ozempic, said the organization, which represents 55 regional poison centers across the country and works with the U.S. Food and Drug Administration to identify public health risks. Ozempic and similar diabetes medicines have been increasingly used off label for weight loss. Novo Nordisk said it did not have insight into the details of these cases.
The FDA has been looking into 22 cases of T-cell cancers that occurred after treatment with CAR-T, Reuters notes, citing an article published in The New England Journal of Medicine by two FDA officials. The publication comes just days after drugmakers were asked to add a serious warning on the label of their cancer therapies that use the CAR-T technology. The officials wrote that secondary malignancies have been reported in conjunction with five of the six available CAR-T products. The cancers included T-cell lymphoma, T-cell large granular lymphocytosis, peripheral T-cell lymphoma, and cutaneous T-cell lymphoma.
Continue to STAT+ to read the full story…
